At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 46 target
Drug / intervention
Cromolyn, TQB2102, and Panpulimabdrug
Likely dose
Cromolyn, TQB2102, and Panpulimab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RECLAIM: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Cromolyn, TQB2102, and Panpulimab for Triple -Negative Breast Cancer. Not yet recruiting, targeting 46 participants across 1 site.
Detailed Summary
RECLAIM: A Phase II, Open-Label, Single-Arm, Multicenter Clinical Trial of Cromolyn, TQB2102, and Panpulimab for Re-Challenging Immune-Refractory Triple-Negative Breast Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple -Negative Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Not Yet Recruiting
20262027
Enrollment StartJan 2026
First PostedFeb 2026
TodayJul 2026
Primary CompletionJan 2027
Study CompletionApr 2027
First PostedFeb 19, 2026
Enrollment StartJan 30, 2026
Primary CompletionJan 30, 2027
Study CompletionApr 30, 2027
TodayJul 1, 2026
Enrollment to primary: 1 yearPosted 4 months agoPrimary completion in 7 months
Interventions
Cromolyn, TQB2102, and Panpulimabdrug
Upon enrollment, patients will receive intravenous administration of penpulimab (200 mg) and TQB2102 (6 mg/kg) every three weeks, along with intranasal delivery of cromolyn sodium (each dose 10 mg \[5 sprays per nostril, bilaterally\], four times daily, administered 30 minutes before meals and at bedtime).